When will Rucaparib be available?

Rucaparib (Rucaparib) was approved byU.S. Food and Drug Administration (FDA) in April 2015 Breakthrough Therapy Certification, and accelerated approval for marketing in December 2016. The drug was subsequently approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults and is sold under the trade name Rubraca. RucapaniThe original drug has not yet been launched in China, so it has not entered the medical insurance coverage standards. Clinical trials have shown that rucapanib has significant efficacy in treating ovarian cancer patients with certain genetic mutations. Especially in patients with ovarian cancer associated with BRCA1 and BRCA2 gene mutations, rucapanib can prolong progression-free survival (PFS) and overall survival (OS).